AXIM BIOTECHNOLOGIES, INC. (AXIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300K 600K 900K Q3 '19: 0 Q4 '19: 799.5K Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 32.6K Q2 '21: 14.9K Q3 '21: 8.1K Q4 '21: 4.8K Q1 '22: 0 Q2 '22: 0 Q3 '22: 1.3K Q4 '22: 7.6K Q1 '23: 7.4K Q2 '23: 9.9K Q3 '23: 9.6K Q4 '23: 12.9K Q1 '24: 53K Q2 '24: 17.5K Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24

Gross Profit Quarterly

-60K 0 60K 120K 180K Q3 '17: 8.1K Q4 '17: 14.7K Q1 '18: 12.5K Q2 '18: 5.9K Q3 '18: 3K Q4 '18: 165.6K Q1 '19: 12.7K Q2 '19: 5.4K Q3 '19: 0 Q4 '19: -18.1K Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 32.6K Q2 '21: 14.9K Q3 '21: 8.1K Q3 '22: 1.3K Q2 '23: 9.9K Q2 '24: 15.7K Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '24

Operating Income Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '19: -483.7K Q4 '19: -568.5K Q1 '20: -688.7K Q2 '20: -662.9K Q3 '20: -1.3M Q4 '20: -2.3M Q1 '21: -868K Q2 '21: -2.2M Q3 '21: -3.3M Q4 '21: -7.6M Q1 '22: -1.1M Q2 '22: -1.1M Q3 '22: -1.3M Q4 '22: -1.1M Q1 '23: -710.6K Q2 '23: -697.7K Q3 '23: -588.5K Q4 '23: -753.9K Q1 '24: -401.6K Q2 '24: -569.4K Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24

Net Income Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '19: -863.6K Q4 '19: -1.4M Q1 '20: -2M Q2 '20: -79.4K Q3 '20: -1.9M Q4 '20: -2.4M Q1 '21: -864.5K Q2 '21: -3.8M Q3 '21: -3.3M Q4 '21: -8M Q1 '22: -2.1M Q2 '22: -1.2M Q3 '22: -2M Q4 '22: -899K Q1 '23: -2.8M Q2 '23: -3.7M Q3 '23: 328.5K Q4 '23: -1.9M Q1 '24: -292.3K Q2 '24: -2.3M Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24

Cost of Revenue Quarterly

0 40K 80K 120K Q3 '16: 13.7K Q4 '16: 113.2K Q1 '17: 38.9K Q2 '17: 1.5K Q3 '17: 1.6K Q4 '17: 797 Q1 '18: 1.7K Q2 '18: 2.3K Q3 '18: 3.2K Q4 '18: 1.3K Q1 '19: 4.4K Q2 '19: 87.6K Q3 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '23: 0 Q2 '24: 1.7K Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q1 '20 Q4 '20 Q2 '24

Operating Cash Flow Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '19: -1.8M Q4 '19: -1.4M Q1 '20: -1.1M Q2 '20: -737.1K Q3 '20: -790.2K Q4 '20: -614.9K Q1 '21: -565.5K Q2 '21: -595.5K Q3 '21: -532.8K Q4 '21: -792.9K Q1 '22: -703.7K Q2 '22: -703.9K Q3 '22: -321.2K Q4 '22: -315.5K Q1 '23: -142K Q2 '23: -643.6K Q3 '23: -264.5K Q4 '23: 19.6K Q1 '24: -252.5K Q2 '24: -261.5K Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24

Free Cash Flow Quarterly

-900K -600K -300K 0 300K 600K 900K Q4 '14: -288.7K Q4 '15: -452.4K Q4 '16: -532.4K Q4 '21: -813.4K Q3 '22: -323.9K Q4 '22: -315.5K Q4 '23: 19.6K Q1 '24: -255.3K Q4 '14 Q4 '15 Q4 '16 Q4 '21 Q3 '22 Q4 '22 Q4 '23 Q1 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q1 '11: 20M Q2 '11: 20M Q3 '11: 20.1M Q1 '12: 33M Q2 '12: 33M Q3 '12: 33M Q2 '13: 33M Q3 '13: 33M Q2 '14: 33M Q3 '14: 33M Q2 '22: 154.9M Q3 '22: 171.9M Q2 '23: 226.3M Q3 '23: 478.5M Q2 '11 Q1 '12 Q3 '12 Q3 '13 Q3 '14 Q3 '22 Q3 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.12 -0.06 0.00 0.06 0.12 0.18 Q3 '19: -0.10 Q4 '19: -0.10 Q1 '20: -0.09 Q2 '20: -0.06 Q3 '20: -0.07 Q4 '20: -0.07 Q1 '21: -0.05 Q2 '21: -0.08 Q3 '21: -0.09 Q4 '21: 0.11 Q1 '22: 0.11 Q2 '22: 0.13 Q3 '22: 0.15 Q4 '22: -0.04 Q1 '23: -0.04 Q2 '23: -0.05 Q3 '23: -0.04 Q4 '23: -0.05 Q1 '24: -0.03 Q2 '24: -0.02 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.